TTKHLTCARE · TTK Healthcare Ltd · Biotechnology & Drugs
TTKHLTCARE · TTK Healthcare Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
26.6% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹258 Cr
Revenue YoY
PAT YoY
+63.7%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
1.4
P/S (TTM)
1.8
Sector P/E
36.3
Dividend yield
+0.9%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| TTKHLTCARE (this stock) | 17.5 | 1.4 | +8.3% | +6.6% | 0.02 | +0.9% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
Not available from data source
MF
0.04% (-1.95pp)
falling 2q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedTTK Healthcare Limited reported a significant increase in revenue and pre-tax profit for FY2022-23, with revenue from continuing operations growing by 21% to Rs.725.11 crores. The company sold its Human Pharma Division for Rs.805 crores, contributing Rs.776.44 crores to pre-tax profit. Despite this, the company faced several disputes related to income tax, customs duty, and excise duty, with pending appeals. The company maintained compliance with corporate governance norms and had no defaults in loan repayments or statutory dues. The CSR obligations were met, with Rs.75 lakhs spent on CSR activities. The auditor noted key audit matters related to revenue recognition and estimates of returns, discounts, and incentives.
- Revenue from continuing operations increased by 21% to Rs.725.11 crores in FY2022-23.
- Pre-tax profit from continuing operations was Rs.61.64 crores, while pre-tax profit from discontinued operations (including the sale of Human Pharma Division) was Rs.776.44 crores.
- The company faced disputes over income tax, customs duty, and excise duty, with pending appeals but no material impact expected.
- CSR obligations were met with Rs.75 lakhs spent on CSR activities.
- No defaults in loan repayments or statutory dues were reported.
Key takeaway: TTK Healthcare Limited achieved strong financial performance in FY2022-23, driven by the sale of its Human Pharma Division and growth in continuing operations, despite facing several tax and duty disputes that are pending resolution.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceRecent (last 12 months)
In the previous financial year 2024-25, the company was fined Rs.2,70,000 each by BSE and NSE plus GST for delayed compliance with Regulation 17(1) of the SEBI (LODR) Regulations, 2015 regarding the composition of the Board of Directors and appointment of a Woman Director, for a period of 54 days from August 23, 2024, to October 15, 2024.
Routine disclosures
Related-Party Transaction
1 occurrenceRecent (last 12 months)
TTK Healthcare Limited had transactions with related parties including T T Krishnamachari & Co., TTK Prestige Limited, Packwell Packaging Products Limited, Pharma Research & Analytical Laboratories, TTK Tantex Limited, and directors including Mr. T T Raghunat.
Statutory dues in dispute
1 occurrenceRecent (last 12 months)
The company has statutory dues under dispute, including amounts demanded under the Central Excise Act and Customs Tariff Act, with pending disputes in various forums as of March 31, 2026.